Home > Healthcare > Medical Devices > Diagnostic Devices > Clinical Chemistry Analyzers Market

Clinical Chemistry Analyzers Market - By Product (Reagents [Buffer, Control], Analyzers [Benchtop, Floor-standing]), Test (Basic Metabolic, Liver, Renal, Lipid Profile), Modality (Centralized, Decentralized), End-use – Global Forecast 2024 - 2032

  • Report ID: GMI8435
  • Published Date: Mar 2024
  • Report Format: PDF

Clinical Chemistry Analyzers Market Size

Clinical Chemistry Analyzers Market size was valued at USD 15.2 billion in 2023 and is estimated to grow at a CAGR of 4.1% between 2024 and 2032. Clinical chemistry analyzers are medical devices used in laboratories to perform chemical analysis of various substances present in biological samples such as blood, serum, plasma, urine, and other bodily fluids. These analyzers utilize advanced techniques and technologies to measure a wide range of biochemical parameters, including electrolytes, enzymes, proteins, metabolites, hormones, lipids, and drugs.
 

Clinical Chemistry Analyzers Market

The increasing prevalence of chronic disorders and lifestyle diseases has emerged as a significant driver for the market. For instance, according to the World Health Organization (WHO) 2023 report, noncommunicable diseases (NCDs) accounted for the deaths of 41 million individuals each year, making up about 74% of all global fatalities. Therefore, there is a surge in demand for enhanced monitoring and treatment options, innovative medical technologies, and comprehensive programs for managing conditions such as cardiovascular diseases, diabetes, obesity, and related disorders.
 

Furthermore, growing adoption of point of care testing signifies a shift towards convenient and rapid diagnostic capabilities, increasing geriatric population, increasing demand for laboratory automation within clinical laboratory services which is estimated to reach USD 409.9 billion by 2032 highlights the need for improving efficiency and scalability in diagnostic testing, among other contributing factors propelling the growth of the market.
 

Clinical Chemistry Analyzers Market Trends

Growing adoption of point of care testing (POCT) in clinical chemistry analyzers signifies a paradigm shift in healthcare delivery, bringing diagnostic testing closer to the patient, improving access to timely and accurate diagnostic information, and ultimately revolutionizing the way healthcare is delivered and managed.
 

  • In chronic disease management, such as diabetes or heart failure, point of care testing enables healthcare providers to monitor patients' health status more closely and adjust treatment plans as needed.
     
  • Furthermore, POCT allows for immediate testing and results delivery, eliminating the need for sample transportation to centralized laboratories and reducing turnaround time.
     
  • Moreover, devices in POCT often include decision support tools and algorithms to assist healthcare providers in interpreting test results and making informed clinical decisions. These decision support features can help optimize treatment strategies, reduce diagnostic errors, and improve patient outcomes.
     

Clinical Chemistry Analyzers Market Analysis

Clinical Chemistry Analyzers Market, By Product, 2021 – 2032 (USD Billion)

Based on product, the market is classified into reagents, analyzers, and other products. The reagents are sub segmented into buffers, calibrators, controls, standards, and other reagents. The analyzers are sub segmented into technology and type. The reagents segment held a market size of 8.2 billion in 2023.
 

  • Reagents are essential components of clinical chemistry analyzers, facilitating accurate and reliable measurement of biochemical parameters in clinical samples.
     
  • Furthermore, reagents are carefully crafted to interact specifically with desired analytes in a sample, reducing the risk of interference from other substances and thereby guaranteeing the precision and dependability of the assay results.
     
  • Moreover, numerous reagents are designed to be compatible with automated systems, facilitating high-throughput testing and enhancing workflow efficiency in clinical laboratories. Thus, these reagents are formulated to meet the stringent requirements of automated platforms, ensuring seamless integration and optimal performance.

 

Clinical Chemistry Analyzers Market, By Test Type (2023)

Based on test type, the clinical chemistry analyzers market is bifurcated into basic metabolic panel, liver panel, renal profile, lipid profile, thyroid function panel, electrolyte panel, and specialty chemical tests. The basic metabolic panel segment is estimated to account for a market size of USD 4 billion by 2032.
 

  • The basic metabolic panel (BMP) is a standard set of tests performed on clinical chemistry analyzers to assess various metabolic and electrolyte parameters in a patient's blood.
     
  • Further, the BMP typically includes tests for glucose, electrolytes, renal function and sometimes calcium and bicarbonate levels. This provides a comprehensive snapshot of a patient's metabolic status, aiding in the diagnosis and management of various medical conditions.
     
  • Moreover, clinical chemistry analyzers can process BMP tests quickly, providing healthcare providers with timely results for immediate clinical decision-making, thereby augmenting the segmental growth of the market.
     

Based on modality, the clinical chemistry analyzers market is categorized into centralized and decentralized. The centralized segment accounted for around USD 6.6 billion revenue size in 2023.
 

  • Centralized analyzers streamline laboratory workflows by automating the analysis of multiple samples using a single instrument.
     
  • Furthermore, centralized analyzers occupy less physical space compared to multiple standalone instruments performing the same functions. This is particularly advantageous for laboratories with limited space or those looking to optimize their workspace.
     
  • Moreover, it offers numerous advantages in terms of efficiency, cost-effectiveness, space-saving, standardization, quality control, integration, and scalability, making them an attractive option for modern clinical laboratories, thereby propelling the segmental growth of market.
     

Based on end-use, the clinical chemistry analyzers market is categorized into hospitals and clinics, specialty clinics, diagnostic laboratories, and other end-users. The hospitals and clinics segment accounted for around USD 5.7 billion revenue size in 2023.
 

  • Clinical chemistry analyzers empower hospitals and clinics with a diverse range of biochemical tests, facilitating effective assessment of patient’s metabolic status, disease monitoring, and treatment guidance.
     
  • Further, with rapid turnaround times for test results, hospitals can diagnose and treat patients promptly. Quick access to diagnostic information facilitates timely interventions, which can be critical for patients in emergency or critical care settings.
     
  • Thus, clinical chemistry analyzers streamline laboratory processes by automating testing procedures and reducing manual labor. This enhances workflow efficiency, allowing hospitals to handle a higher volume of tests and deliver results to healthcare providers more promptly, thereby contributing to the growth of the market.

 

North America Clinical Chemistry Analyzers Market, 2020 – 2032 (USD Billion)

North America clinical chemistry analyzers market accounted for USD 6.5 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

  • The region has a large aging population, growing adoption of point of care testing devices, increasing demand for laboratory automation are influencing the development of market.
     
  • Growing prevalence of chronic disorders such cardiovascular diseases, diabetes, cancer is estimated to augment market growth. For instance, according to the Centers for Disease Control and Prevention (CDC) in 2021, approximately 695,000 people in the U.S. died from heart disease.
     
  • Further, North America boasts a highly developed healthcare infrastructure characterized by state-of-the-art medical facilities and advanced diagnostic technologies, fosters widespread adoption and utilization of clinical chemistry analyzers across various healthcare settings.
     

Clinical Chemistry Analyzers Market Share

The clinical chemistry analyzers industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
 

Clinical Chemistry Analyzers Market Companies

Some of the eminent market participants operating in the clinical chemistry analyzers industry include:       

  • Abbott Laboratories                                
  • Danaher Corporation
  • EKF Diagnostics
  • F.Hoffmann-La Roche Ltd.                                 
  • Hitachi Ltd.             
  • HORIBA Ltd.
  • Ortho Clinical Diagnostics                                   
  • QuidelOrtho Corporation
  • Siemens Healthineers AG
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.                  
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
     

Clinical Chemistry Analyzers Industry News:

  • In May 2023, Siemens Healthineers introduced the Atellica HEMA 570 and 590 analyzers for high-volume hematology testing. The company benefited by expanding its product portfolio and meeting the growing demand for testing solutions.
     
  • In May 2022, Mindray introduced the BS-600M chemistry analyzer, enhancing productivity and reliability for medium-volume laboratories. The company benefited by expanding its product line and addressing the needs of a broader market segment, potentially increasing market share and revenue.
     

The clinical chemistry analyzers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report


Market, By Product

  • Reagents
    • Buffers
    • Calibrators
    • Controls
    • Standards
    • Other reagents 
  • Analyzers
    • By technology
      • Semi-automatic analyzers
      • Fully automatic analyzers
      • Point of care analyzers
    • By type
      • Benchtop analyzers
      • Floor-standing analyzers 
  • Other products

Market, By Test Type

  • Basic metabolic panel
  • Liver panel
  • Renal profile
  • Lipid profile
  • Thyroid function panel
  • Electrolyte panel
  • Specialty chemical tests

Market, By Modality

  • Centralized
  • Decentralized

Market, By End-use

  • Hospitals and clinics
  • Specialty clinics
  • Diagnostic laboratories
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of Middle East and Africa

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global clinical chemistry analyzers market was valued at USD 15.2 billion in 2023 and is estimated to record a CAGR of 4.1% between 2024 and 2032, driven by the increasing prevalence of chronic disorders and lifestyle diseases.

The centralized segment accounted for around USD 6.6 billion revenue size in 2023, as it offers numerous advantages in terms of efficiency, cost-effectiveness, space-saving, standardization, quality control, integration, and scalability.

North America clinical chemistry analyzers industry accounted for USD 6.5 billion revenue in 2023, attributed to growing prevalence of chronic disorders such cardiovascular diseases, diabetes, and cancer.

Abbott Laboratories, Danaher Corporation, EKF Diagnostics, F.Hoffmann-La Roche Ltd., Hitachi Ltd., HORIBA Ltd., Ortho Clinical Diagnostics, QuidelOrtho Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Sysmex Corporation, and Thermo Fisher Scientific Inc.

Clinical Chemistry Analyzers Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 343
  • Countries covered: 22
  • Pages: 200
 Download PDF